Clinical Trials Using Idelalisib

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Idelalisib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-10 of 10
  • Study to Evaluate Safety and Preliminary Efficacy of MOR208 With Idelalisib or Venetoclax in R / R CLL / SLL Patients Pretreated With BTKi (COSMOS)

    This is a two-cohort, multicenter, open-label study of MOR00208 combined with idelalisib or venetoclax in adult patients with R / R CLL or R / R SLL pretreated with a BTK inhibitor (e.g., ibrutinib) as single agent or as part of combination therapy.
    Location: 3 locations

  • Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

    The primary objectives of this study are to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of tirabrutinib (ONO / GS-4059) in combination with other targeted anti-cancer therapies in adults with relapsed or refractory B-cell lymphoproliferative malignancies. This study consists of two parts: Dose Escalation and Dose Expansion. During the dose escalation phase, participants will be sequentially enrolled in a standard 3 + 3 dose escalation study design, to receive oral tirabrutinib combined with idelalisib entospletinib + / - obinutuzumab. The Dose Expansion Phase will enroll additional participants with a single B-cell lymphoproliferative malignancy disease type to further evaluate efficacy, safety, tolerability, PK, and pharmacodynamics.
    Location: 2 locations

  • Pembrolizumab Alone or with Idelalisib or Ibrutinib in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

    This phase II trial studies how well pembrolizumab alone or with idelalisib or ibrutinib works in treating patients with chronic lymphocytic leukemia or other low-grade B-cell non-Hodgkin lymphomas that have returned after a period of improvement or have not responded to treatment. Monoclonal antibodies, such as pembrolizumab, block cancer growth in different ways by targeting certain cells and allow the immune system to attack the cancer. Idelalisib and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab alone or with idelalisib or ibrutinib may be an effective treatment in patients with chronic lymphocytic leukemia or other low-grade B-cell non-Hodgkin lymphomas.
    Location: 2 locations

  • Phase 1b Safety and Efficacy Study of TRU-016

    The purpose of this study is to evaluate the efficacy and safety of TRU-016 in combination with rituximab, in combination with obinutuzumab, in combination with rituximab and idelalisib, or in combination with ibrutinib in patients with CLL; and in combination with bendamustine in patients with PTCL.
    Location: 2 locations

  • Idelalisib in Treating Patients with B Cell Malignancies after Donor Bone Marrow Transplant

    This phase I trial studies the side effects of idelalisib in treating patients with B cell malignancies after donor bone marrow transplant. Idelalisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL

    This is a phase Ib multi-center, open-label study: escalation part followed by expansion part. The primary purpose of the Phase Ib CBCL201X2102C study is to characterize the safety and tolerability of BCL201 combined with idelalisib in patients with FL and MCL. Approximately 65 patients are to be enrolled. The primary endpoint for the Phase Ib is frequency, severity and seriousness of AEs, lab abnormalities and other safety parameters such as ECG changes. An adaptive Bayesian logistic regression model (BLRM) will guide the dose escalation to determine the MTD / RDE in phase Ib. In addition Bayesian regression models will be used to estimate the dose-exposure relationships for both BCL201 and idelalisib in order to guide the escalation steps. A Bayesian method for the expansion part will be used for the primary activity objective. The study data will be analyzed and reported based on all patients' data of the escalation and expansion part.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Dose Optimization Study of Idelalisib in Follicular Lymphoma

    This study will optimize the safety and efficacy of chronic administration of idelalisib in participants with follicular lymphoma (FL) and evaluate the overall safety profile of idelalisib and the overall response rate (ORR) by Week 24.
    Location: See Clinical

  • Idelalisib and Ofatumumab in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    This phase II trial studies how well giving idelalisib and ofatumumab together works in treating patients diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who have not received any previous treatment. Idelalisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as ofatumumab, may find cancer cells by identifying a protein on the surface of the cells and help kill them. Giving idelalisib and ofatumumab together may help stop the growth of disease in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Location: 4 locations

  • Mechanisms of Idelalisib-Associated Diarrhea in Patients with Relapsed Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, or Small Lymphocytic Lymphoma

    This research trial studies the mechanisms of idelalisib-associated diarrhea in patients with chronic lymphocytic leukemia, indolent non-Hodgkin lymphoma, or small lymphocytic lymphoma that has come back after a period of improvement. The cancer treatment drug idelalisib triggers diarrhea in some patients. Studying stool, blood, and tissue samples in the lab from patients who are given idelalisib may help doctors learn more about the side effects and may help to treat them in future patients.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

    This study is to provide idelalisib (IDELA) to individuals with relapsed, previously treated chronic lymphocytic leukemia (CLL) who have limited treatment options and are not eligible for other Gilead-sponsored studies.
    Location: See Clinical